Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice
Open Access
- 1 July 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 10 (7) , 377-388
Abstract
Intestinal cyclic guanosine monophosphate (cGMP) signaling regulates epithelial homeostasis and has been implicated in the suppression of colitis and colon cancer. In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model. Treatment of mice with sildenafil activated cGMP signaling in the colon mucosa and protected against dextran-sulfate sodium (DSS)-induced barrier dysfunction. In mice treated with AOM/DSS, oral administration of sildenafil throughout the disease course reduced polyp multiplicity by 50% compared with untreated controls. Polyps that did form in sildenafil treated mice were less proliferative and more differentiated compared with polyps from untreated mice, but apoptosis was unaffected. Polyps in sildenafil treated mice were also less inflamed; they exhibited reduced myeloid-cell infiltration and reduced expression of iNOS, IFNγ, and IL6 compared with untreated controls. Most of the protection conferred by sildenafil was during the initiation stage of carcinogenesis (38% reduction in multiplicity). Administration of sildenafil during the later promotion stages did not affect multiplicity but had a similar effect on the polyp phenotype, including increased mucus production, and reduced proliferation and inflammation. In summary, the results demonstrate that oral administration of sildenafil suppresses polyp formation and inflammation in mice treated with AOM/DSS. This validation of PDE5 as a target highlights the potential therapeutic value of PDE5 inhibitors for the prevention of colitis-driven colon cancer in humans. Cancer Prev Res; 10(7); 377–88. ©2017 AACR. See related editorial by Piazza, p. 373.Keywords
All Related Versions
Funding Information
- NCI (#CA17262701A1)
This publication has 51 references indexed in Scilit:
- PKG II Inhibits EGF/EGFR-Induced Migration of Gastric Cancer CellsPLOS ONE, 2013
- GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier IntegrityPLOS ONE, 2012
- Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma modelProceedings of the National Academy of Sciences, 2011
- Loss of Guanylyl Cyclase C (GCC) Signaling Leads to Dysfunctional Intestinal BarrierPLOS ONE, 2011
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 2011
- PKG inhibits TCF signaling in colon cancer cells by blocking β-catenin expression and activating FOXO4Oncogene, 2010
- Immunity, Inflammation, and CancerCell, 2010
- The Hormone Receptor GUCY2C Suppresses Intestinal Tumor Formation by Inhibiting AKT SignalingGastroenterology, 2010
- Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal CancerJAMA, 2009
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionJournal of Experimental Medicine, 2006